Despite the high burden of hepatitis C virus (HCV)-related morbidity and mortality among HIVpositive people who use illicit drugs (PWUD), uptake of interferon-based treatments for HCV infection has been negligible among this group. Direct-acting antiviral (DAA) therapies offer an opportunity to expand treatment access among this population. The aim of this study was to explore willingness to use DAA-based regimens among HIV/HCV-coinfected PWUD in Vancouver, Canada.
Introduction
As a consequence of shared routes of transmission, HIV and hepatitis C virus (HCV) coinfection is common, with approximately 3-12% of the 36.9 million people living with HIV (PLWH) globally being coinfected with HCV [1] . Among PLWH, people who use drugs (PWUD) are disproportionately affected by HCV infection, with the prevalence of coinfection [i.e. HCV antibody (Ab) positivity] ranging between 50% and 90%, leading to interrelated epidemics of HIV, HCV and substance use disorders [2, 3] . In Canada, coinfection estimates for HIV-positive PWUD are > 80% [1] .
Several studies show that dual infection with HIV and HCV may negatively impact the course of the other disease. In particular, PLWH are less likely to spontaneously clear HCV infection, and also experience accelerated rates of progression to end-stage liver disease, hepatocellular carcinoma, and death [2, 4] . Indeed, HCV-related disease has become one of the leading causes of morbidity and mortality among PLWH, particularly in regions where antiretroviral therapy (ART) is widely available [5] . Importantly, HCV eradication [i.e. sustained virological response (SVR)] is associated with significant reductions in HCV-related morbidity and all-cause mortality [4, 6] . Treatment of HCV has therefore become a priority for this population [7, 8] .
Despite the high burden of HCV disease among HIVinfected PWUD, and their role as key drivers of HCV transmission in many settings [9] , access and uptake of HCV treatment among this population have been consistently low [10, 11] . Factors contributing to this low uptake include barriers at the patient (e.g. fear of side effects and cost), provider (e.g. discrimination and misconception of PWUD's potential to adhere) and macrostructural (e.g. criminalization of drug use and low access to treatment) levels [12] . Furthermore, until recently most HCV treatment guidelines systematically excluded PWUD from HCV treatment [7] .
Encouragingly, in recent years, increasing success of HCV treatment among PWUD has contributed to a reversal of this trend. In particular, empirical evidence has indicated that, when appropriately supported, PWUD achieve similar rates of SVR compared to the general population [13, 14] . As a result, many international bodies, including the World Health Organization [15] , the American Association for the Study of Liver Disease (AASLD)/Infectious Diseases Society of America (IDSA) [16] , and the European Study for the Association of the Liver (EASL) [17] , now recommend HCV treatment for PWUD.
The increasing availability of direct-acting antiviral (DAA) agents has marked a shift in the paradigm of HCV treatment from lengthy and poorly tolerated interferonbased regimens to highly efficacious (regardless of HIV status), safer and shorter all-oral regimens [18] . This shift has brought renewed optimism regarding the prospects of controlling the HCV epidemic [8] . Given the key role that HIV/HCV-coinfected PWUD play in perpetuating the HCV epidemic, expanding access to HCV treatment to this population should be a public health priority [7, 9] , as optimal deployment of DAA-based HCV therapy to PWUD will offer the dual benefit of improving individual HCV clinical outcomes (e.g. reduced HCV-related morbidity and mortality) and reducing the risk of onward HCV transmission [19] . The feasibility of scaling up access to HCV treatment among HIV/HCV-coinfected PWUD depends, at least in part, on their willingness to use DAA-based treatments. However, to our knowledge, this issue has never been systematically assessed. Thus, the objective of this study was to examine the prevalence and correlates of willingness to use DAA-based regimens among a community-based cohort of HIV/HCV-coinfected PWUD in Vancouver, Canada.
Materials and methods

Study design and population
Data for this study were drawn from the AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS), an ongoing prospective cohort of HIV-positive adults who use illicit drugs in Vancouver, Canada that began recruitment in 2005, and that has been described in detail previously [20, 21] . In brief, individuals are eligible for inclusion if they are HIV-positive, ≥ 18 years old, live within greater Vancouver, and have used illicit drugs other than cannabis in the previous month. Participants are recruited through snowball sampling and extensive street outreach with a focus in the Downtown Eastside neighbourhood, an area with an open drug market and high levels of illicit drug use, poverty and HIV/HCV infection.
After providing written informed consent, at baseline and on a semi-annual basis thereafter, participants complete an interviewer-administered questionnaire, provide blood samples for serological testing (e.g. HCV antibodies), and are examined by a study nurse, who provides referrals to health services when needed. The questionnaire elicits information on sociodemographic characteristics, drug use patterns, health care access and utilization, including HIV, HCV and addiction care, and other relevant exposures. Starting in June 2014, questions regarding knowledge about HCV and willingness to use new DAAs were added to the questionnaire. In addition, as has been described elsewhere [20] , information gathered at each semi-annual visit is augmented by confidential data linkages with the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) Drug Treatment Program, which provides HIV care, including free ART, to all PLWH in the province of British Columbia. These linkages allow a complete longitudinal clinical and laboratory profile for each participant to be obtained, including all CD4 counts, plasma HIV viral load (VL) tests, and ART dispensation. Participants receive a CAD$ 30 stipend at each study visit. The ACCESS study has received ethical approval from the University of British Columbia/Providence Health Care Research Ethics Board. The analytical sample for the current study was restricted to HCV-seropositive participants who completed at least one study visit between June 2014 and May 2015. In the event of multiple observations for one individual, the most recent observation was used.
Measures
The primary outcome of interest was willingness to use DAA-based regimens, defined as responding "yes" to the question: "New HCV treatments have been developed that take less time, are more likely to cure you and have fewer side effects. If these became available to you, would you be interested in taking them?" Participants who responded affirmatively to this question were subsequently asked to indicate their treatment willingness under the following efficacy scenarios: < 40, 40-59, 60-79 and > 80%.
We selected a range of explanatory variables that, based on previous studies, were hypothesized to influence uptake of HCV treatment among PLWH and PWUD [3, [22] [23] [24] . Sociodemographic characteristics considered included: age at baseline (per year older); gender (male vs. female); and self-reported indigenous ancestry (including self-reporting First Nations, M etis or Inuit ancestry, yes vs. no). We also considered substance use behaviours including high-intensity injecting drug use (≥ daily vs. < daily); high-intensity noninjecting drug use (≥ daily vs. < daily); and heavy alcohol use (≥4 drinks/ day vs. < 4 drinks/day), as well as living in unstable housing conditions, defined as living in a single-room occupancy hotel, shelter, hostel or treatment/recovery house, living on the street or having no fixed address. Access to and utilization of health services, as well as clinical status, were explored through the following variables: assessment by an HCV specialist; engagement in methadone maintenance therapy (MMT); other addiction treatments (i.e. detox, recovery house, counselling, 12-step programmes and residential treatment); use of ART (≥1 day ART dispensed, using pharmacy refill data); and HIV viral load suppression, defined as having an HIV viral load < 50 HIV-1 RNA copies/mL plasma (yes vs. no) in the previous 6 months. In the case of multiple VL measurements within a 6-month follow-up period, the median of all the observations was utilized. This number was then used to dichotomize participants with < or ≥ 50 copies/mL as virally suppressed or not, respectively, for that period. In the event of no tests in the 6-month period, individuals were defined as suppressed if they were ART-exposed and dispensation records indicated that they had been dispensed medications for the entire period (i.e. ≥ six pick-ups of medication.) Finally, we examined previous exposure to HCV treatment, and participants' perceptions of the impact of HCV on their health. Except for the sociodemographic variables and previous exposure to HCV treatment, all other variables refer to the 6-month period prior to the follow-up visit of interest.
Statistical analysis
First, we described characteristics of participants stratified by their willingness to receive DAA-based regimens. To examine bivariable associations between each independent variable and the outcome of interest, we then used the bivariable logistic regression. Next, to determine the independent correlates of willingness to receive DAA-based regimens, we fitted a multivariable logistic model, using an a priori-defined backward stepwise procedure that has been used extensively in several earlier studies [25] . Starting with a full model containing all variables associated with the outcome at P < 0.10 in bivariable analyses, the Akaike information criterion (AIC) of the model is noted, and the variable with the largest P-value is dropped to fit a reduced model. This iterative process is continued until no variables are left. The model with the lowest AIC value is selected as the final model. Unadjusted and adjusted odds ratios (AORs) with 95% confidence intervals (CIs) are reported. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
Results
Between June 2014 and May 2015, 572 HIV-positive PWUD completed at least one study visit, of whom 418 (73%) were HCV-seropositive and provided valid answers to the primary outcome, and thus were included in the present study. Characteristics of study participants stratified by willingness to use DAA-based regimens are presented in Table 1 . The median age was 44 years [interquartile range (IQR) 37-48 years], and 265 (63%) were male. Access to and utilization of relevant health care were heterogeneous, as reflected by the fact that, although the majority were on ART (395; 95%) and two-thirds had seen an HCV specialist in the last 6 months (279; 67%), only about half were enrolled in MMT (220; 53%), and < 10% had ever been treated for HCV (39; 9%). Overall, 295 participants (71%) reported that they would be willing to use DAA-based regimens. As expected, as hypothetical efficacy scenarios increased, more participants would consider HCV treatment: ranging from 12% in a < 40% efficacy scenario to 47% for a > 80% efficacy scenario (Fig. 1) . Table 2 shows the results of unadjusted and adjusted logistic regression analyses of factors associated with willingness to use DAA-based regimens. In bivariable analyses, engagement in MMT, recent assessment by an 
Discussion
In this study, we found a high prevalence of willingness to use DAA-based regimens among HIV/HCV-coinfected PWUD in Vancouver, Canada. In particular, engagement in addiction (i.e. MMT) and HCV care (i.e. recent assessment by an HCV specialist), as well as holding the perception that HCV was affecting the participant's health, were associated with increased odds of reporting willingness to use DAAs. To our knowledge, this is the first study to assess willingness to use DAA-based regimens among HIV/ HCV-coinfected PWUD, a key population within the HCV epidemic. Previous studies among HCV-monoinfected PWUD have shown similarly high proportions (up to 86%) of willingness to use HCV treatment, even with older, less efficacious and poorly tolerated interferonbased regimens [3, [22] [23] [24] . This high willingness to undergo HCV treatment contrasts with historical low HCV treatment access and uptake among PWUD [10, 11] , suggesting a substantial unmet need in HCV treatment coverage for this population. For example, a recent survey among Canadian HCV specialists found that < 20% would consider offering HCV treatment to individuals actively injecting drugs [26] . This is highly concerning as expanding access to optimized HCV treatment to PWUD is a potentially highly cost-effective public health intervention, given the increased risk of HCV-related progression (particularly among PWUD coinfected with HIV) and associated health care costs, and given the key role that PWUD play in HCV transmission [19, 27] . Taken together, these findings highlight the urgent need for interventions to ensure equitable access to HCV care for PWUD. These should include educating health care providers, reducing costs of HCV treatment, simplifying HCV care delivery, integration with HIV and addiction services, and the removal of punitive criminal laws and policies against PWUD [28] [29] [30] .
In line with past research, engagement in MMT was associated with increased willingness to use DAA-based regimens [22, 24] . A more stable lifestyle afforded by reduced opioid use and dependence symptoms, as well as frequent contact with health services (e.g. daily supervised ingestion of methadone), may result in a subpopulation of PWUD who are more ready and amenable to consider engaging in HCV treatment. Indeed, a growing number of studies suggest that opioid agonist treatment programmes may serve as an important platform to engage PWUD with opioid use disorders in the HCV continuum of care [31] . In contrast, we did not find any impact on willingness to use DAAs of other addiction treatment approaches with less evidence base, including psychosocial-only interventions or withdrawal management alone strategies. Taken together, these results support global calls to expand and sustain access to opioid agonist treatment as part of a broader public health effort to address the interrelated epidemics of HIV, HCV and substance use disorders [15, 32] . Also, these findings underscore the urgent need to identify and develop effective pharmacotherapies for stimulant use disorders to improve addiction treatment outcomes, which, in turn, may be of benefit to support engagement in HCV care for this population [33] .
Absence of symptoms or limited knowledge about the natural history of HCV infection and its treatment have been described as important individual-level barriers to treatment uptake [12, 23, 28, 34] . Therefore, it is not surprising that, in line with previous work, participants in our study who perceived that HCV was affecting their health were more willing to consider HCV treatment [23] . Similarly, higher willingness to use DAA-based regimens among HIV/HCV-infected PWUD with a recent assessment by an HCV specialist might be a reflection of greater knowledge about their HCV disease status (e.g. HCV RNA and fibrosis stage), and risks/benefits of treatment as a result of information and assessments provided by the HCV specialist. These findings emphasize the key role that a trusting and respectful relationship between patients and health care providers may play in informing and supporting patients throughout the process of decision-making about HCV treatment [23, 28, 34] . Accordingly, educational activities tailored to both patients and providers may help improve uptake of HCV treatment among PWUD. In particular, educational activities tailored to health care providers may reduce stigmatizing interactions with PWUD (e.g. misconceptions about PWUD's potential to adhere to treatment), a major obstacle to the initiation of discussions about the potential benefits of HCV treatment for this population. Ultimately, successful scale-up of HCV treatment will rely, at least in part, on the readiness of HCV care providers and patients to engage in evidence-informed dialogues about HCV treatment.
This study has a number of limitations. First, as our sample was not randomly selected, results from this study may not be generalizable to other populations of HIV/HCV-coinfected PWUD. In particular, more hidden subpopulations of PWUD may be underrepresented in this sample. Secondly, as a consequence of the crosssectional nature of this study, we were unable to determine temporal and causal relationships between the explanatory variables and outcome. For instance, this could be the case for the relationship between assessment by an HCV specialist and willingness to use DAAbased regimens, which could have suffered from reverse causality. Thirdly, many measures for these analyses relied on self-reported data, which can be subject to social-desirability and recall biases. We attempted to mitigate these potential sources of biases by ensuring that all interviews were conducted in confidential environments by experienced interviewers with strong community rapport. Past research indicates that PWUD's reports in these conditions are reliable [35, 36] . Finally, because of the lack of systematic access to HCV RNA measurements and tests for liver fibrosis staging (e.g. transient elastography), we were not able to evaluate the number of participants with chronic HCV infection or who would be eligible for publicly funded HCV treatment under current Canadian guidelines (e.g. > F2) [37] . However, giving increasing rates of progression to chronic HCV infection (up to 85%) and end-stage liver disease (ESLD) among HIV/HCV-coinfected individuals, it is anticipated that a large proportion would meet these eligibility criteria.
In summary, this study found high rates of willingness to use DAA-based regimens among HIV/HCVinfected PWUD in this setting. Bridging the gap between PWUD's HCV treatment willingness and actual treatment uptake should be a priority for this population moving forward. Importantly, enrolment in MMT was positively associated with willingness to use newer HCV treatments. This finding, alongside previous successful experiences of integration of HIV, HCV and addiction treatment, suggests that multidisciplinary one-stop-shop models of care for PWUD may play a critical role in increasing access to HCV treatment and improving treatment outcomes among this population [29] [30] [31] . The role of addiction treatment in HCV treatment and prevention outcomes should therefore be further explored [14] . The impact of new DAA-based regimens on the HCV epidemic will remain limited as long as so-called core transmitters, including HIV/HCV-coinfected PWUD, are not prioritized for access to optimized treatment for HCV infection.
